This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Novo Nordisk A/s, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2021-2023.
Company Filing History:
2 out of 1,801 
2 out of 3,693 
Years Active: 2021-2023
Title: Anna Wolska: Innovator in Hypertriglyceridemia Treatment
Introduction
Anna Wolska is a prominent inventor based in Washington, DC. She has made significant contributions to the field of medicine, particularly in the treatment of hypertriglyceridemia. With a total of 2 patents, her work focuses on innovative solutions that address critical health issues.
Latest Patents
Wolska's latest patents include the development of apolipoprotein C-II (apoC-II) mimetic peptides. These peptides are designed to provide effective treatment for patients suffering from hypertriglyceridemia. The disclosure emphasizes methods for administering an effective amount of these mimetic peptides to achieve desired health outcomes.
Career Highlights
Throughout her career, Anna Wolska has worked with notable organizations, including the United States Department of Health and Human Services and Novo Nordisk A/S. Her experience in these institutions has allowed her to contribute to significant advancements in medical research and treatment methodologies.
Collaborations
Wolska has collaborated with esteemed colleagues such as Chih-Hung Lo and Alan Thomas Remaley. These partnerships have further enhanced her research and development efforts in the medical field.
Conclusion
Anna Wolska's innovative work in developing treatments for hypertriglyceridemia showcases her dedication to improving patient health. Her contributions through patents and collaborations highlight her role as a key figure in medical innovation.